... Property Office (SIPO) revoked Gilead Sciences's patent for Viread (tenofovir), a treatment for hepatitis B and HIV/AIDS, after a challenge from local active pharmaceutical ingredient (API) manufacturer Aurisco. SIPO stated that Viread is not a ...
http://www.wirenews.co/asia/pharmaceuticals/13847/recently-released-market-study-china-pharmaceuticals-healthcare-report-q4-2013
http://www.wirenews.co/asia/pharmaceuticals/13847/recently-released-market-study-china-pharmaceuticals-healthcare-report-q4-2013
No comments:
Post a Comment